High-level Expression and Purification of Tat-haFGF19-154

Yadong Huang,Yulan Rao,Chengli Feng,Yanmei Li,Xiaoping Wu,Zhijian Su,Jian Xiao,Yechen Xiao,Wenke Feng,Xiaokun Li
DOI: https://doi.org/10.1007/s00253-007-1249-5
IF: 5
2008-01-01
Applied Microbiology and Biotechnology
Abstract:Human acidic fibroblast growth factor (haFGF) stimulates repair and regeneration of central and peripheral nerves after various injuries. However, it is unable to cross the blood–brain barrier (BBB). To produce a therapeutic haFGF with cell-permeable activity, we fused the haFGF19-154 gene with Tat-PTD. After its construction by a single-step insertion of a polymerase chain reaction (PCR)–amplified coding sequence, the vector pTat-haFGF19-154-His was expressed in Escherichia coli BL21 (DE3) cells. The optimal expression level of the soluble fusion protein was up to 36.7% of the total cellular protein. The recombinant Tat-haFGF19-154-His was purified by a combination of Ni–NTA affinity, Sephadex G-25, and heparin affinity chromatography to 95% as detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The final yield was 171 mg/l culture. Purified Tat-haFGF19-154-His had distinct mitogenic activity in Balb/c 3T3 cells, as measured by methylthiazoletetrazolium (MTT) assay and its ED50 was 3.931 × 10−4 µmol/l. Tat-haFGF19-154-His protein intravenously injected at the dose of 10 mg/kg could be detected in the pallium and hippocampi.
What problem does this paper attempt to address?